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SYNOPSIS 
Routine laryngeal examination after total thyroidectomy is not cost-effective against selective 
laryngeal examination done at 2-week, 1-month or 3-month after surgery. Selective laryngeal 
examination done at 3-month appears to be a reasonable selective strategy given its lowest 
overall cost. 
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ABSTRACT 
Background 
Although routine laryngeal examination (RLE) after thyroidectomy may cost more than selective 
laryngeal examination (SLE), it permits earlier detection and treatment of vocal cord palsy (VCP) 
and so may be cost-saving in the longer term. We compared the 2-year cost-effectiveness 
between RLE, SLE with LE done at 2 weeks (SLE-2w), 1-month (SLE-1m) and 3-month (SLE-
3m) after thyroidectomy in the institution’s perspective. 
Methods 
Our case definition was a hypothetical 50 year-old female who underwent an elective total 
thyroidectomy for a benign multinodular goiter. A decision-analytic modelling was constructed 
to compare the estimated cost-effectiveness between RLE, SLE-2w, SLE-1m and SLE-3m after a 
2-year period. Outcome probabilities, utilities and costs were estimated from the literature. The 
threshold for cost-effectiveness was set at USD50,000/quality-adjusted life year (QALY). 
Sensitivity and threshold analyses were used to examine model uncertainty. 
Results 
RLE was not cost-effective because its incremental cost-effectiveness ratio to SLE-2w, SLE-1m 
and SLE-3m were USD302755, USD227883 and USD247105, respectively. RLE was only cost-
effective when temporary VCP rate increased >42.7% or cost of LE equaled zero. Similarly, 
SLE-2w was only cost-effective to SLE-3m when dysphonia for temporary VCP at 3-month 
increased >39.13%, dysphonia for permanent VCP at 3-month increased >50.29% or dysphonia 
without VCP at 3-month increased >42.69%. However, none of these scenarios appeared 
clinically likely. 
Conclusions 
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In the institution’s perspective, RLE was not cost-effective against the other 3 SLE strategies. 
Regarding to the optimal timing of SLE, SLE-3m appears to be a reasonable and acceptable 
strategy because of its relative low overall cost.
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INTRODUCTION 
Thyroidectomy is one of the most commonly-performed surgical procedures and because 
postoperative vocal cord paresis or palsy (VCP) is an important procedural-related complication, 
information on the patient’s postoperative vocal cord status is essential [1-4]. However, 
postoperative routine laryngeal examination (RLE) of the vocal cords (VC) remains 
controversial [1-4]. Although most surgeons would perform selective laryngeal examination 
(SLE) (i.e. laryngeal examination (LE) when voice symptoms/dysphonia have become persistent 
for some time after thyroidectomy), some prefer RLE [5-8]. A recent large audit has found the 
frequency of postoperative LE ranges between 0 to 100% [8].  
One reason for such divided practice is the issue of cost-effectiveness in RLE as this has never 
been demonstrated [1-4]. Although RLE would cost more than SLE because more LE are done, 
recent studies have found that RLE permits earlier diagnosis and treatment of VCP (such as 
injection thyroplasty) (IT) and so may be cost-saving in the longer term [9-12]. Furthermore, 
unlike SLE, RLE greatly shortens the duration of dysphonia minimizing the loss of patient 
quality of life (QOL) (i.e. more effective) [9,13]. Therefore, RLE may prove more cost-effective 
than SLE in the longer term. The other issue is related to the timing of the SLE strategy as this 
could range between 2 weeks to 3 months from thyroidectomy [1-4,9]. Although an early LE 
would lead to an earlier diagnosis and treatment of VCP, it may increase the detection and 
treatment of VCP which are mostly temporary and fully recoverable without treatment [5,14]. 
Based on these arguments, a decision-tree analysis model was constructed to examine whether 
RLE was cost-effective to SLE over a medium term and also to find out the optimal cost-
effective timing for the SLE strategy.  
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MATERIALS AND METHODS 
A decision tree model using TreeAge Software Pro version 2013 (Treeage Software, Inc., 
Williamstown, MA, US) was constructed to compare the 2-year estimated cost-effectiveness 
between two main strategies, namely RLE and SLE after elective total thyroidectomy. Under the 
RLE strategy, all postoperative patients were subjected to LE within 1-2 days after operation. 
This was regardless of their voice quality or symptoms. As a result, the cause of dysphonia was 
made early and that led to early IT (for those with dysphonia and VCP) or speech therapy (for 
those with dysphonia but no VCP). In contrast, under the SLE strategy, only a select group of 
patients with persistent voice complaints or dysphonia for a period of time would undergo LE. 
As a result, the cause of dysphonia was not made until LE was performed after a period of 
dysphonia and that varied between 2 weeks to 3 months [1-4,9]. Since dysphonia rate and 
temporary VCP would decrease over time, the SLE was further divided into 3 sub-strategies to 
account for these time-related changes. They were SLE at 2-week (SLE-2w), at 1-month (SLE-
1m), and at 3-month (SLE-3m) after thyroidectomy. Therefore, our model comprised four 
strategies, namely RLE, SLE-2w, SLE-1m, and SLE-3m. Figure 1 outlines the decision-analytic 
modelling.  
Base-case patient 
A 50 year-old female patient underwent an elective total thyroidectomy for a moderately 
enlarged but non-retrosternal benign multinodular goiter. She did not have any preoperative 
voice symptoms or VCP. Also she did not have any previous head and neck surgery or 
irradiation. Both recurrent laryngeal nerves (RLN) were clearly visualized and appeared intact at 
the end of thyroidectomy. 
Data sources 
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Estimates of temporary and permanent VCP after total thyroidectomy were derived from pooling 
results of a recent systematic review and two recent large thyroid surgery registries [8,15,16]. 
The total number of patients pooled was 47,564. VCP rates were calculated based on number of 
patients rather than nerves-at-risk. Other probabilities of outcomes such as rates of postoperative 
dysphonia with and without VCP, recovery rate of temporary VCP and chance of permanent 
vocal cord medialization with and without IT at 2-week, 1-month, and 3-month were derived 
from a comprehensive PubMed search using free text search terms in ‘All fields’. These search 
terms included ‘dysphonia’, ‘vocal cord palsy’, ‘injection thyroplasty’ and ‘vocal cord 
medialization’. There was no language restriction or methodological filters. The bibliography of 
a recent clinical practice guideline on voice outcomes after surgery was also searched for 
additional relevant references [9]. Critical appraisal of each study was performed by 2 authors 
(BHL,CKW). Expert opinion was sought from 2 specialist otolaryngologists (RYT,BYW) if the 
outcome probabilities were not available in the literature. The range obtained from the experts 
was used to guide the sensitivity analysis if it was a more reliable source of information. Base-
case values were derived by pooling the results of all retrieved studies. If only one study was 
available, the mid-point of the reported range was taken. Table 1a summarizes outcome 
probabilities. 
Utilities 
Effectiveness was measured by quality-adjusted life years (QALYs) gained. QALY adjusts the 
life-expectancy through the multiplication of QOL adjustment with duration stayed at each 
health state. The QOL adjustment is quantified by a utility score that typically ranges from 0 
(death) to 1 (full health). Table 1b lists the utility score for each health state. In the present study, 
utilities were used as weights to calculate quality-adjusted life expectancy. A utility of 1.0 was 
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assigned for a patient that underwent elective total thyroidectomy without dysphonia while 0.81 
was assigned to any health state with the outcome of “dysphonia” after thyroidectomy regardless 
of cause [13]. 
Study design and decision models 
The analysis was designed from an institution’s perspective, using QALYs as the overall 
outcome measure. For each strategy, QALYs was the sum of two components, namely the time 
period stayed in full health (i.e. without dysphonia) multiplied by 1.0 and the time of dysphonia 
multiplied by the utility score of 0.81 within a 2-year period.  
Cost data 
Our model only looked at the cost of four strategies (i.e. RLE, SLE-2w, SLE-1m, and SLE-3m) 
from an institution’s perspective. Total cost included procedural cost and complication cost. 
Indirect costs such as loss of productivity and wages were not included. Unit costs of LE, speech 
therapy, office-based IT and VC medialization under general anesthesia were estimated based on 
Medicare reimbursement for surgical procedure obtained from public access file from Centers 
for Medicare and Medicaid Services [17-19] and data obtained from previous cost-effectiveness 
analysis [20]. Table 1c summarizes the unit costs.  
Assumptions 
All LE were performed by expert otolaryngologists using standard technique without 
complications or discomfort. All VCP were assumed unilateral only because bilateral would not 
have been clinically silent. Patients with asymptomatic VCP were assumed to have a utility score 
of 1 (i.e. the state of a healthy individual without VCP). For patients with symptomatic VCP 
confirmed on LE, IT was given immediately without delay while those with dysphonia without 
VCP were given speech therapy. One single IT was assumed adequate for complete voice 
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recovery in symptomatic VCP. ML was performed for permanent VCP 12 months after 
thyroidectomy. 
Base-case analysis 
This was done according to the established guideline for cost-effectiveness analysis [21]. The 
incremental cost-effectiveness ratio (ICER) was the only outcome measurement and equaled to 
[cost of strategy A – cost of strategy B] / [QALYs of strategy A – QALYs of strategy B]. A 
strategy was “cost-saving” if it was costing less and also more effective over the competing 
strategy (i.e. that strategy dominated the competing strategy). A strategy was regarded cost-
effective over another strategy if the ICER was < USD50,000 per QALY gained. This threshold 
was chosen based on analysis of the cost of current healthcare resource allocation decisions in 
the US [22]. A strategy was regarded as “extended dominance” if it was less effective and had a 
higher ICER than one of the competing strategies.  
Sensitivity analysis  
Univariate sensitivity analysis was performed to evaluate the impact of various outcome 
probabilities on the base-case analysis. Strategies that had extended dominance in the base-case 
analysis were eliminated from the sensitivity analysis. Each clinical parameter varied from the 
lowest to the highest values as suggested in the literature while other parameters remained 
constant. Since RLE would cost more than SLE, a negative incremental effectiveness meant SLE 
was dominant. A threshold analysis was undertaken to capture the threshold clinical values at 
which the ICER of RLE relative to SLE became zero (cost equivalence favoring the RLE) or less 
than USD50,000 per QALY gained (RLE was cost-effective relative to SLE). The range of 
threshold analysis was considerably expanded by adopting the theoretical range from 0 to 100%. 
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RESULTS 
Base-case analysis 
Table 2 shows the results of base-case analysis. After a 2-year period, each patient in RLE spent 
an extra USD110.20 but gained an additional 0.00036 QALY over SLE-2w. Therefore, the RLE 
was more costly but also more effective than SLE-2w in the institution’s perspective. However, 
since the ICER of USD302755 for RLE relative to SLE-2w was far above the recommended 
threshold, RLE was not more cost-effective than SLE-2w. RLE was also not cost-effective to the 
other 2 SLE sub-strategies as the ICER of RLE relative to SLE-1m, and SLE-3m were 
USD227883 and USD247105, respectively. By definition, SLE-1m was regarded as extended 
dominance because it was less effective than SLE-2w, and had a higher ICER ($364,022/QALY 
vs $161,994/QALY) than SLE-2w when comparing with SLE-3m. Therefore, SLE-1m was 
excluded from subsequent sensitivity analyses. 
Sensitivity analysis 
Table 3 shows the univariate sensitivity analysis of RLE vs. SLE-2w and SLE-2w vs. SLE-3m. 
Regarding to the comparison between RLE and SLE-2w, RLE remained not cost-effective to 
SLE-2w when key clinical parameters such as rates of VCP, dysphonia and permanent ML after 
IT were varied. Varying these parameters still yielded positive ICERs well above the threshold 
of 50,000 implying RLE was not cost-effective. RLE only became cost-saving to SLE-2w if the 
cost of LE became zero. For the comparison between SLE-2w and SLE-3m, SLE-2w became 
cost-effective to SLE-3m if rates of permanent VCP increased to 18.6%, dysphonia either in 
temporary or permanent VCP at 3-month increased to 80.6%, or dysphonia without VCP at 3-
month increased to 87.0%. However, since the permanent VCP rate could not rise above the 
temporary VCP rate, this was excluded from the subsequent threshold analysis. 
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Table 4 shows the threshold analyses of RLE vs. SLE-2w and SLE-2w vs. SLE-3m. RLE 
became cost-effective to SLE-2w if temporary VCP after total thyroidectomy increased from 
7.12% to 42.74% (i.e. around 6 times) (see appendix 1). SLE-2w became cost-effective to SLE-
3m if dysphonia in temporary VCP at 3-month increased > 39.13% (see appendix 2). Other 
scenarios included dysphonia in permanent VCP at 3-month increased >50.29% and dysphonia 
without VCP at 3-month increased >42.69%. 
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DISCUSSION 
Given the controversies with RLE, the present study is the first ever attempt at evaluating 
whether RLE could be cost-effective relative to the three different SLE strategies based on 
timing of LE. In terms of cost per person, RLE was unsurprisingly the most costly strategy 
against the other strategies. Relative to the lowest cost strategy (SLE-3m), RLE cost 5.8 times 
more. This was because under the RLE strategy, more patients were subjected to postoperative 
LE whereas under the SLE-3m strategy, only those with persistent dysphonia for 3 months were 
subjected to postoperative LE. In fact, there was a gradual decrease in cost per person as the 
timing of SLE became delayed (from 2-week to 3-month). This was because fewer LE were 
required over time as the rate of dysphonia decreased over time. In addition, since most VCPs 
were temporary (i.e. neurapraxia) and tended to recover spontaneously (without treatment), the 
actual number of VCP detected and required IT under the SLE-3m strategy were among the 
lowest. In fact, by 2 months, more than 60% of temporary VCP would have recovered without 
any treatment or intervention [14]. Although the chance of having more expensive VC 
medialization in delayed LE might be higher because of delayed diagnosis and treatment of VCP, 
our data showed that this did not greatly increase the overall cost as suggested by previous 
studies [9-12].  
In terms of effectiveness, RLE was also the most effective strategy because all VCP and 
dysphonia would have been diagnosed and managed within days after thyroidectomy whereas 
under the three SLE strategies, there was gradual loss of QOL over time because patients 
suffered longer duration of dysphonia and lower chance of normal voice recovery. However, 
despite being the most effective strategy based on these arguments, RLE was not cost-effective 
to SLE-2w, SLE-1m and SLE-3m. 
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Both the sensitivity and threshold analyses of RLE vs. SLE-2w showed that almost none of the 
reported ranges in clinical parameters affected our conclusion unless the cost of LE was reduced 
to zero or temporary VCP increased significantly to 42.7% (i.e. 6 times higher than the reported 
rate). In contrast, the threshold analysis of SLE-2w vs. SLE-3m did find three possible scenarios 
which were within the reported ranges and could potentially make SLE-2w cost-effective to 
SLE-3m. However, they were probably clinically unlikely because it is unusual to have such 
high percentage of postoperative patients complaining of persistent dysphonia 3 months after 
surgery irrespective of the cause of dysphonia [23-28].  
Therefore, RLE was not cost-effective against the other 3 SLE strategies. Relative to the other 2 
SLE strategies, SLE-3m appears a more reasonable and acceptable strategy because of its low 
cost. 
However, despite these results, we do acknowledge several shortcomings. Firstly, our model did 
not account for potential benefits of self-auditing in RLE (i.e. the surgeon could learn his/her 
own RLN injury rates and improve) [1,2]. Although this may not affect the present injury rates, it 
would reduce future injuries and so in the longer term, RLE may prove cost-effective relative to 
SLE strategies. Secondly, some of the assumptions might have been over-simplified. For 
example, patients with asymptomatic VCP do not necessarily have a normal health state (utility 
score of 1.0) as subtle changes affecting QOL loss are possible. Also it is arguable whether every 
patient with VCP/dysphonia requires immediate IT. Close observation might be more 
appropriate in mild dysphonia. In actual practice, VCP could be bilateral and 2-3 thyroplasties 
are often required to manage severely symptomatic VCP [10-12]. Also the latter is not 
necessarily free of complications/discomfort. Nevertheless, most of these would only have 
increased the ICER of RLE relative to SLE strategies. Also, some of the newer developments 
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(e.g. laryngeal electromyography) in characterizing severity and prognosis of VCP were not 
included and despite a comprehensive literature search, selection and publication biases could 
not be completely ruled out as none of the studies examined were randomized studies.  
CONCLUSION 
RLE could not be recommended based on cost-effectiveness unless temporary VCP rate 
increased by 6 times or cost of LE was reduced to zero. Regarding to the optimal timing for SLE 
strategy, SLE-2w could only become cost-effective to SLE-3m if dysphonia necessitating LE 
remained very high (>40%) at 3-month. Therefore, in the institution’s perspective, RLE was not 
cost-effective against the other 3 SLE strategies. Relative to the other 2 SLE strategies, SLE-3m 
appears a more reasonable strategy given its relative low overall cost. 
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Table 1a. Literature-based probabilities 
Clinical Parameters Base case (%) Range for sensitivity 
analysis (%) 
Reference 
Unilateral vocal cord palsy after total thyroidectomy (%) 
- Temporary  
- Permanent  
 
7.1 
2.0 
 
1.4 – 38.4 
0.0 – 18.6 
 
8,15,16  
8,15,16 
Dysphonia rate in the presence of temporary or permanent 
unilateral vocal cord palsy (%) 
- at 2-week 
- at 1-month 
- at 2-month 
- at 3-month 
 
 
50.5 
40.5 
30.5 
20.5 
 
 
20.4 – 80.6 
20.4 – 80.6 
20.4 – 80.6 
20.4 – 80.6 
 
 
9,29,experts 
9,29,experts 
9,29,experts 
9,29,experts 
Dysphonia rate without vocal cord palsy (%) 
- at 2- week 
- at 1-month 
- at 2-month 
- at 3-month 
 
44.1 
34.1 
24.1 
14.1 
 
14.0 – 87.0 
14.0 – 87.0 
14.0 – 87.0 
14.0 – 87.0 
 
23-28,30,31,experts 
23-28,30,31,experts 
23-28,30,31,experts 
23-28,30,31,experts 
Recovery rate for temporary vocal cord palsy (%) 
- at 2-week 
- at 1-month 
- at 2-month 
- at 3-month 
 
29.6 
46.1 
62.5 
68.8 
 
29.6 
46.1 
62.5 
68.8 
 
14 
14 
14 
14 
22 
 
Rate of permanent vocal cord medialization based on the 
delay from injury to first injection thyroplasty (%) 
- 2 week to < 1 month 
- 1 month to < 2 month 
- 2 month to < 3 month 
- 3 month to < 4 month 
 
 
0 
20.0 
33.3 
33.3 
 
 
0.00 – 26.3 
20.0 – 26.3 
26.3 – 37.5 
26.3 – 37.5 
 
 
10-12 
10-12 
10-12 
10-12 
 
Table 1b. Utility score for each health state in model 
Health state in model Utility Score Reference 
Post-thyroidectomy patients 
-no dysphonia 
-dysphonia 
 
1.00 
0.81 
 
13 
13 
 
Table 1c. Unit cost (USD) for each service component for post-thyroidectomy 
Cost component  Unit cost in USD Reference 
Laryngeal examination of the vocal cords 115.52 17-19 
Speech therapy 102.6 17-19 
Injection laryngoplasty under local anesthesia (office-
based) 
496.00 17-19 
Permanent vocal cord medialization under general 
anesthesia 
4511.80 17-19 
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Table 2. Cost (USD) and quality-adjusted life expectancy (QALYs) per person for each laryngeal examination strategy, and the 
incremental cost-effective ratio (ICER) (USD/QALYs) of a laryngeal examination strategy compared with other competing strategies 
after elective total thyroidectomy. 
  Laryngeal examination strategies* 
 
Routine laryngeal 
examination 
Selective laryngeal 
examination at 2-week 
Selective laryngeal 
examination at 1-month 
Selective laryngeal 
examination at 3-month 
Cost (USD) per person 179.471 69.268 61.655 30.714 
Incremental cost compared 
with routine laryngeal 
examination 
- 110.203 117.816 148.757 
Expected QALYs per 
person 
2.000 1.99964 1.99948 1.99940 
Incremental 
QALYs/100,000 persons 
compared with routine 
laryngeal examination 
- 36 52 60 
 
Competing Laryngeal examination strategy 
ICER (cost/QALYs) 
Routine laryngeal 
examination  
Selective laryngeal 
examination at 2-week  
Selective laryngeal 
examination at 1-month  
Selective laryngeal 
examination at 3-month  
Routine laryngeal 
examination  
- 302755 227883 247105 
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Selective laryngeal 
examination at 2-week  
- - Extended dominance 161994 
Selective laryngeal 
examination at 1-month  
- - - 364022 
*Sort by descending order of QALYs  
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Table 3. Sensitivity analysis between routine laryngeal examination (RLE), selective laryngeal examination at 2-week (SLE-2w) and 
at 3-month (SLE-3m) after thyroidectomy. 
 
RLE vs. SLE-2w 
 
SLE-2w vs. SLE-3m 
Clinical Parameters Parameter 
Range (%) 
Incremental 
QALYs/100
,000 persons 
Range for ICER Incremental 
QALYs/100,
000 persons 
Range for ICER 
Unilateral vocal cord palsy after total thyroidectomy (%) 
- Temporary VCP  1.4 – 38.4 14 161 836877.75 56941.82 
 
14 78 215002.98 110603.74 
- Permanent VCP  0.0 – 18.6 28 103 391219.23 97751.28 
 
12 119 337303.45 10714.22 
Dysphonia rate in the presence of temporary unilateral vocal cord palsy (%) 
- at 2-week 20.4 – 80.6 19 53 633351.00 181817.30 
 
41 7 62438.57 757128.30 
- at 3-month 20.4 – 80.6 36 36 302452.87 302452.87 
 
24 143 163611.87 8634.37 
Dysphonia rate in the presence of permanent unilateral vocal cord palsy (%) 
- at 2-week 20.4 – 80.6 32 41 359378.25 258658.92 
 
29 19 122228.76 221766.07 
- at 3-month 20.4 – 80.6 36 36 302452.87 302452.87 
 
24 81 162885.09 16389.93 
Dysphonia rate without vocal cord palsy (%) 
- at 2-week 14.0 – 87.0 36 36 379485.55 192662.10  24 24 44079.14 330211.18 
- at 3-month 14.0 – 87.0 36 36 302452.87 302452.87  24 24 162451.57 Favoring 
SLE-2w 
Rate of permanent vocal cord medialization based on the delay from injury to first injection thyroplasty (%) 
- 2 week to < 1 month 0.00 – 26.3 36 36 302452.87 269666.93  24 24 162059.61 212273.37 
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- 3 month to < 4 month 26.3 – 37.5 36 36 302452.87 302452.87  24 24 167484.96 158804.41 
Cost component 
Laryngeal examination  0 – 1000 36 36 Favoring 
RLE 
2618186.1
8 
 24 24 148783.23 263710.38 
Speech therapy 0 – 1000 36 36 302452.87 302452.87  24 24 44471.10 1190557.96 
Injection laryngoplasty 
under local anesthesia 
(office-based) 
0 – 1000 36 36 302452.87 302452.87  24 24 105055.75 219982.90 
Permanent cord 
medialization under 
general anesthesia 
0 – 1000 36 36 302452.87 302452.87  24 24 187868.76 182148.39 
Abbreviations: QALYs = Quality-adjusted life-years; ICER = Incremental cost-effectiveness ratio 
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Table 4. Threshold analysis of values at which routine laryngeal examination (RLE) became cost-effective to selective laryngeal 
examination at 2-week (SLE-2w) or SLE-2w became cost-effective to selective laryngeal examination at 3-month (SLE-3m) 
RLE vs. SLE-2w 
Clinical Parameters Base-
case (%) 
Threshold 
values at 
ICER=50,000 
Values at 
ICER>50,000 
Values at ICER 
between 0 and 
50,000 
RLE became 
cost-saving 
RLE became 
cost-saving 
Unilateral vocal cord palsy after 
total thyroidectomy 
7.120 42.741 0.000-42.741 42.741-100.000 NA NA 
 SLE-2w vs. SLE-3m 
Clinical Parameters Base-
case (%) 
Threshold 
values at 
ICER=50,000 
Values at 
ICER>50,000 
Values at ICER 
between 0 and 
50,000 
SLE-2w 
became cost-
saving 
SLE-2w 
became cost-
saving 
Dysphonia rate in temporary vocal cord palsy (%) 
   - at 3-month 20.5 39.131 8.551-39.131 39.131-100.000 NA 0.000-8.551 
Dysphonia rate in permanent vocal cord palsy (%) 
- at 3-month 20.5 50.291 0.000-50.291 50.291-100.000 NA NA 
Dysphonia rate without vocal cord palsy (%) 
- at 3-month 14.1 42.689 0.000-42.689 42.689-55.446 55.446-
100.000 
NA 
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LEGENDS 
 
Figure 1. The decision-analytic modelling.  
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Appendix 1. One way-sensitivity analysis of the incremental cost-effectiveness ratio (ICER) of 
routine laryngeal examination (RLE) over selective laryngeal examination at 2-week (SLE-2w) 
as a function of rate of temporary vocal cord palsy after total thyroidectomy. The dashed line 
represents the 50,000/QALY threshold for cost-effectiveness.  
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Appendix 2. One way-sensitivity analysis of the incremental cost-effectiveness ratio (ICER) of 
selective laryngeal examination at 2-week (SLE-2w) over SLE at 3-month (SLE-3m) as a 
function of dysphonia in the presence of temporary vocal cord palsy at 3-month after total 
thyroidectomy. The dashed line represents the 50,000/QALY threshold for cost-effectiveness. 
 
